Efficacy of Low-Dose Heparin in Prevention of Extensive Deep-Vein Thrombosis in Patients Undergoing Total-Hip Replacement

S, Sagar; Stamatakis, J. D.; Higgins, April; Nairn, David; Maffei, Francisco H.A.; Thomas, Duncan P.; Kakkar, Vijay V.

doi:10.1016/s0140-6736(76)91541-5

Cited by 150 publications

(40 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1][2][3][4][5][6][7] Most of these series were of cemented prostheses; it is possible therefore that cement may have thrombogenic properties and so influence the incidence of DVT. Reports concerning this are conflicting; activation of the clotting cascade and concurrent fibrinolysis have been described during and after TKR and THR, 8,9 but it is uncertain whether this activation is different in cemented compared with uncemented prostheses.…”

mentioning

confidence: 99%

Cement as a risk factor for deep-vein thrombosis

Clarke

Green

Harper

et al. 1998

The Journal of Bone and Joint Surgery. British volume

View full text Add to dashboard Cite

A total of 110 total knee replacements (TKRs) was randomised to receive either a cemented or an uncemented prosthesis. Postoperative venography at five to seven days was used to compare the prevalence, site and size of deep-vein thrombosis (DVT). We also compared the findings with those of postoperative venography in a group of patients with cemented total hip replacements (THRs).The total prevalence of DVT was significantly greater after uncemented (81%) than after cemented TKR (55%). Both knee groups had a significantly higher prevalence of DVT than in cemented hip replacements (32%). We found no difference in the proportion with proximal DVT in the three groups (14%, 15% and 16%). The median length of the thrombi was significantly greater after cemented (26.5 cm) than after uncemented TKR (11 cm) or after cemented THR (7 cm). This difference was mainly due to greater lengths of distal rather than proximal thrombi.We conclude that the use of cement may affect the formation of DVT after joint replacement, but does not appear to lead to an increased incidence.

show abstract

mentioning

confidence: 99%

Cement as a risk factor for deep-vein thrombosis

Clarke

Green

Harper

et al. 1998

The Journal of Bone and Joint Surgery. British volume

View full text Add to dashboard Cite

show abstract

“…Sagar et al [14] could not either confirm the findings of H ampson et al [7] with their prolonged heparin prophylaxis. This might be a disadvantage with heparin, since we have seen increasing resistance from nurses and patients to continue 8-hourly injections after the end of the first postoperative week.…”

Section: Discussionmentioning

confidence: 82%

Sulfinpyrazone and Postoperative Deep Vein Thrombosis

Gruber¹,

Buser²,

Frick³

et al. 1977

Eur Surg Res

View full text Add to dashboard Cite

Small doses of subcutaneous heparin and infusions of dextran both reduce the incidence of fatal pulmonary embolism after elective general surgery. But both methods have disadvantages. Therefore, the protection against deep vein thrombosis afforded by sulfínpyrazone, a drug which can be taken by mouth as well as by injection, was assessed in a prospective study of 119 patients undergoing elective general or urological surgery. The prophylactic administration of sulfínpyrazone was compared with the effects of small doses of sodium heparin and infusions of dextran-70. The ¹²⁵I-fibrinogen test was carried out in all patients during their hospitalization. Deep vein thrombosis was diagnosed in 13 of 30 patients (43%) who received sulfínpyrazone, in 9 of 29 (31%) receiving dextran-70 and in 2 of 22 (9%) having subcutaneous heparin. The difference between the sulfínpyrazone and heparin groups was statistically significant (p < 0.01). Sulfínpyrazone in the dose used in this trial was not effective in reducing the incidence of deep vein thrombosis during elective general surgery.

show abstract

“…The risk of thrombosis increases when the functional activity of AT is reduced to less than 80% of normal levels [16]. The level of AT in heterozygotes is generally between 40 to 70% of normal levels [4].…”

Section: Antithrombin Deficiencymentioning

confidence: 99%

Thrombophilia: the dermatological clinical spectrum

Criado¹,

Duarte²,

Magalhães³

et al. 2016

Glob Dermatol

View full text Add to dashboard Cite

The aim of this article is to review the hypercoagulable states (thrombophilia) most commonly encountered by dermatologists, as well as their cutaneous signs, including livedo racemosa, cutaneous necrosis, digital ischemia and ulcerations, reticulated purpura, leg ulcers, and other skin conditions. Recognizing these cutaneous signs is the first step to proper treatment. Our aim is to describe which tests are indicated, and when, in these clinical settings.

show abstract

Efficacy of Low-Dose Heparin in Prevention of Extensive Deep-Vein Thrombosis in Patients Undergoing Total-Hip Replacement

Cited by 150 publications

References 30 publications

Cement as a risk factor for deep-vein thrombosis

Cement as a risk factor for deep-vein thrombosis

Sulfinpyrazone and Postoperative Deep Vein Thrombosis

Thrombophilia: the dermatological clinical spectrum

Contact Info

Product

Resources

About